- NIH acknowledges KEI/UACT request to use royalty-free or march-in rights on Xtandi
- Feasibility study on a TDR pooled fund for R&D to be released on 20 February 2016
- SAVE THE DATE - 26 January 2016: Implications of the TPP and RCEP on Universal Health Coverage
- Xtandi 2016 March-In Request
- Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes
- 51 members of Congress have asked the NIH to use March-In rights to rein in high drug prices
- WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual property
- FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit
- KEI's December 19, 2015 submission to the US ITC regarding the TPP
- The UK's rebates on drug sales, and introducing the budget constraint into pricing models
The California Assembly Health Committee has published an analysis of AB463, the Pharmaceutical Cost Transparency Act of 2015. The bill will be marked up by the committee on Tuesday (April 21). The analysis was written by Dharia McGrew. It recommends three amendments to the bill, and provides a discussion of the benefits of the required disclosures, with context, and describes the support and opposition. The staff report is attached, and below is a list of 33 groups supporting and 22 opposing the bill.
Knowledge Ecology International (KEI) will present the following statement on 20 April 2015 to the Open Session of the 20th Expert Committee on the Selection and Use of Essential Medicines.
Statement of Knowledge Ecology International: WHO 20th Expert Committee on the Selection and Use of Essential Medicines, with specific focus on expanding access to new cancer drugs, when available at affordable prices
20 April 2015
Dear members of the WHO Expert Committee and the WHO secretariat,
State of California considers AB463, a bill to require disclosure of drug development costs, and more economic dataSubmitted by James Love on 17. April 2015 - 6:35
This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.
A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.
BILL NUMBER: AB 463
INTRODUCED BILL TEXT
INTRODUCED BY Assembly Member Chiu
FEBRUARY 23, 2015
This from the Wikileaks Sony Archive:
An email from Keith Weaver, the "Executive Vice President, Worldwide Government Affairs at Sony Pictures Entertainment, provide an illustration the practical art of doing "Government Affairs," meeting "goals" for fundraisers, trying to avoid making "personal" contributions, and wondering if the donations were to much focused on another company's purchase of policy" "smells a little bit like a Disney play regarding corp. tax reform".
From: Weaver, Keith
Sent: Tuesday, August 26, 2014 5:23 PM
To: Weil, Leah
Sony referred to "WIPO treaty for blind as "stalking horse" to "denigrate the rights of copyright owners"Submitted by KEI Staff on 16. April 2015 - 13:32
In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (https://wikileaks.org/sony/docs/05/docs/DECE/DECE%20CP1%20-%20ss.doc.pdf), which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:
The following attached letter [PDF ], from KEI and Public Citizen, asks the NIH to impose certain conditions on an exclusive license on NIH owned patents for a drug to treat the hepatitis C virus (HCV). The NIH wants to license the patents to Virotas Biopharmaceuticals, LLC, a company having a place of business in California. Other than the patents involved, the NIH requires people to sign a non-disclosure to know more about the deal.
TRIPS Council (October 2014): India calls for de-linkage and innovation inducement prizes at WTO discussions on IP & innovationSubmitted by thiru on 30. March 2015 - 3:25
In advance of the World Trade Organization's October 2014 session of the TRIPS Council, the European Union, Switzerland and the United States made a written request to the TRIPS Council to discuss "Intellectual Property and Innovation: Promoting Awareness; Case Studies" under agenda item 12. This marked the 7th time that the United States tabled an item to the TRIPS Council relating to intellectual property or innovation.
In the context of these October 2014 discussions of Intellectual Property and Innovation, the Government of India delivered the following intervention asserting that,
Twenty groups write Congress, no fast track without public access to trade agreement negotiating textsSubmitted by James Love on 20. March 2015 - 15:09
Twenty groups, including KEI, have written Congress, asking the Congress to provide public access to draft trade agreement texts and U.S. proposals throughout negotiations, and to specific that only agreements developed through such processes should obtain any expedited congressional consideration.
Among other things, the groups said:
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies -- AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.
HRC28: Statement of the European Union- Cultural Rights (Response to SR Report on Copyright and Right to Science and Culture)Submitted by thiru on 12. March 2015 - 10:56
On Wednesday, 11 March 2015, Oliver Hall-Allen, First Counsellor, Delegation of the European Union to the United Nations Office in Geneva delivered the following statement in response to the presentation of the Special Rapporteur in the Field of Cultural Rights (Farida Shaheed) on her Report on Copyright policy and the right to science and culture (A/HRC/28/57).
Oliver Hall-Allen (blue tie, white shirt), First Counsellor, Delegation of the European Union to the United Nations Office in Geneva
HRC28: Statement of the United States of America - Cultural Rights (Response to SR Report on Copyright and Right to Culture)Submitted by thiru on 11. March 2015 - 18:19
On Wednesday, 11 March 2015, Ambassador Keith Harper, U.S. Representative to the Human Rights Council, delivered the following statement to the 28th Session of the Human Rights Council on the topic of cultural rights.
HRC28: Statement by Farida Shaheed, Special Rapporteur, on Copyright policy and the right to science and cultureSubmitted by thiru on 11. March 2015 - 5:45
On Wednesday, 11 March 2015, Farida Shaheed, the United Nations Special Rapporteur in the field of cultural rights presented her seminal report on Copyright policy and the right to science and culture (A/HRC/28/57) at the 28th session of the Human Rights Council in Geneva.
Highlights from the report's recommendations include the following:
WTO at 20: Symposium on the TRIPS Agreement for TRIPS Council Members and Observers (26 February 2015)Submitted by thiru on 4. March 2015 - 11:22
As part of the World Trade Organization's (WTO) technical assistance and capacity building program, on Thursday, 26 February 2015, the WTO Secretariat convened a Symposium on the TRIPS Agreement for TRIPS Council Members and Observers which brought together negotiators from the 1986–94 Uruguay Round to discuss how the Round introduced intellectual property norms into the architecture of the multilateral trading system. In addition, other experts were brought in to discuss what has happened since the introduction of the TRIPS Agreement, and what augurs for the future.
St Jude holds 24 patents with influenza in the specification, that also disclose US government rights. Some of these were discussed here: http://keionline.org/node/2188
PAT. NO. Title
1 8,574,592 Modified influenza virus for monitoring and improving vaccine efficiency
2 8,551,481 Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
3 8,309,099 DNA transfection system for the generation of negative strand RNA virus
Our 2009 FOIA request, and 42 pages of CDC emails debating what to give us.
The February 17, 2015 cover letter from CDC.
The 184 page CDC foia response, which we received in February 2015. Note that we were particularly interested in the patent issues related to reverse genetics.